Unlocking global access to liquid biopsy through in-country testing

Bringing Guardant360® to China, supporting the standardization of global clinical trials.

Through our partnership with Adicon Labs, one of the top 3 labs in China with an integrated network, we can:

• Support local testing in the development of new therapies
• Expand patient screening and accelerate recruitment for biopharma companies with commercial and regulatory expertise

Growing the list of CDx approvals in Japan with Guardant360 CDx.

Guardant360 CDx has MHLW approval and is reimbursed under the National Health Insurance system in Japan.

Partnering with world-renowned cancer centers in Europe, enabling access to Guardant360.

Our partnership model provides access to in-country CGP testing and is helping to accelerate testing adoption and reimbursement in Spain, the UK, and Italy.

Guardant360® CDx has received CE certification under the
European Union In Vitro Diagnostic Regulation (IVDR) , including CDx indications identifying patients for targeted therapy in NSCLC and breast cancer, and for tumor profiling across all solid tumors.

CDx, companion diagnostic; CGP, comprehensive genomic profiling; NSCLC, non-small cell lung cancer; MHLW, Ministry of Health, Labor, and Welfare.